Welcome to our dedicated page for Aligos Therapeutics SEC filings (Ticker: ALGS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Aligos Therapeutics, Inc. (NASDAQ: ALGS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical stage biotechnology issuer focused on liver and viral diseases. These documents include current reports on Form 8-K, annual and quarterly reports, and other materials that describe Aligos’ operations, capital structure, and governance.
Aligos files Form 8-K current reports to announce material events such as financial results, annual meeting outcomes, amendments to its certificate of incorporation, and changes to equity incentive plans. For example, the company has reported quarterly financial results and detailed stockholder votes on proposals to increase authorized shares of voting and non-voting common stock, as well as amendments to its 2020 Incentive Award Plan. These filings outline how Aligos manages its share capital and equity-based compensation.
Through its periodic reports, Aligos discusses its status as a clinical stage biotechnology company developing therapeutics for chronic hepatitis B virus infection, obesity, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses. Investors can use these filings to understand the company’s pipeline focus, research and development spending, and other aspects of its business model. The filings also confirm that Aligos’ common stock, with a par value of $0.0001 per share, is listed on The Nasdaq Stock Market LLC (Nasdaq Capital Market) under the symbol ALGS.
On Stock Titan, SEC filings for ALGS are complemented by AI-powered summaries that highlight key points from lengthy documents. These tools help readers quickly identify information on topics such as clinical program updates, capital structure changes, and stockholder approvals, while still allowing access to the full-text filings as made available through the EDGAR system.
Aligos Therapeutics reported that officer Julian A. Symons received a grant of stock options as part of his compensation. The award covers 23,310 stock options to buy Aligos common stock at an exercise price of $7.03 per share.
These options were granted on March 9, 2026 and vest over time. According to the terms, 1/48th of the options vest each month, starting from March 9, 2026, so that the entire grant becomes fully vested and exercisable on the fourth anniversary of that date, if he continues in service through each vesting date.
Aligos Therapeutics, Inc. principal accounting officer Nikhil Aneja received a grant of stock options covering 9,450 shares of common stock at an exercise price of $7.0300 per share. These options were awarded as compensation and do not represent an open-market purchase or sale.
According to the vesting terms, 1/48th of the total options vest in equal monthly installments starting on March 9, 2026, so all 9,450 options are scheduled to be fully vested and exercisable by the fourth anniversary of that vesting commencement date, contingent on continued service.
Aligos Therapeutics, Inc. reported a compensation-related stock option grant to officer Lesley Ann Calhoun. She was awarded options to acquire 37,485 shares of common stock at an exercise price of $7.03 per share, expiring on March 9, 2036.
According to the vesting terms, 1/48th of the options vest in equal monthly installments starting on March 9, 2026, so the grant becomes fully vested and exercisable on the fourth anniversary of that date, subject to her continued service. This filing reflects an acquisition of derivative securities, not an open-market purchase or sale of common shares.
Aligos Therapeutics, Inc. director and President & CEO Lawrence Blatt received a stock option grant covering 105,840 shares of common stock. The option has an exercise price of $7.03 per share and represents a right to buy, not a market purchase.
According to the vesting terms, 1/48th of the total shares vest in equal monthly installments starting on March 9, 2026, so the option becomes fully vested and exercisable on the fourth anniversary of that date, subject to his continued service. Following this award, he holds 105,840 stock option rights directly in this filing.
Aligos Therapeutics reported a 2025 net loss of $24.2 million, sharply improved from $131.2 million in 2024, mainly due to a non-cash $60.2 million gain from revaluing 2023 common warrants. Operating expenses remained high, with research and development at $69.5 million and general and administrative at $20.7 million.
Cash, cash equivalents and short-term investments totaled $77.8 million as of December 31, 2025, and the company used $82.5 million in operating cash during the year. Management expects existing funds to last only into the third quarter of 2026 and discloses substantial doubt about its ability to continue as a going concern without additional financing.
Aligos raised gross proceeds of $92.1 million in an October 2023 PIPE and approximately $105.0 million in a February 2025 private placement, while advancing its clinical-stage pipeline, including the Phase 2 B-SUPREME trial of HBV candidate pevifoscorvir sodium and Phase 2 work on MASH and coronavirus programs.
Aligos Therapeutics reported recent pipeline progress and sharply improved 2025 financial results. Cash, cash equivalents and investments were $77.8 million as of December 31, 2025, which the company expects will fund planned operations into the third quarter of 2026.
Net loss narrowed to $19.9 million for the fourth quarter of 2025, compared with $82.2 million a year earlier. For the full year 2025, net loss fell to $24.2 million from $131.2 million, helped by $60.2 million of income from the change in fair value of 2023 common warrants.
In its HBV portfolio, the Phase 2 B-SUPREME study of pevifoscorvir sodium completed planned enrollment of 60 HBeAg- participants, with HBeAg+ enrollment ongoing and topline data expected in 2027. ALG-170675 was advanced into IND-enabling studies with partner Amoytop, while preclinical data for ALG-055009 showed additional weight loss when combined with incretin therapies. Aligos also added an Executive Vice President, Chief Commercial Officer to build commercial capabilities.
Aligos Therapeutics, Inc. reported the initial holdings of Principal Accounting Officer Nikhil Aneja on a Form 3. The filing lists several stock option awards giving the right to buy 3,800, 2,640, 7,155 and 3,600 shares, each vesting over four years based on continued service.
Aligos Therapeutics, Inc. received an updated ownership report showing that investment adviser Woodline Partners LP beneficially owns 289,169 shares of Aligos voting common stock, representing 5.4% of the class. This percentage is based on 5,353,582 shares outstanding as of October 31, 2025.
The shares are directly held by Woodline Master Fund LP, for which Woodline Partners serves as investment adviser. Woodline states the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Aligos.
Sio Capital Management, LLC filed an amended Schedule 13G reporting a passive ownership stake in Aligos Therapeutics, Inc.. Sio beneficially owned 335,937 shares of Aligos common stock as of December 31, 2025, representing 5.46% of the class, based on 6,153,582 shares outstanding as of October 31, 2025. Sio is an investment adviser to affiliated funds that directly hold the shares and has shared voting and dispositive power over them. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Aligos.
Aligos Therapeutics, Inc. announced that its Board of Directors appointed Nikhil Aneja as the company’s Principal Accounting Officer, effective immediately. He replaces Lesley Ann Calhoun in that specific role, while she continues as Executive Vice President, Chief Operating Officer and Chief Financial Officer.
Mr. Aneja, age 49, has been Aligos’s Vice President, Finance since February 2024. His background includes senior finance and controller positions at CareDx, Blade Therapeutics and Global Blood Therapeutics, and he is a Certified Public Accountant with a Bachelor of Commerce from the University of Delhi.